Pharma companies are spending billions on AI for drug discovery, and the results are already showing up in clinical trials. But the real question isn’t “can AI find new drugs?” It’s “who owns the data that makes AI find drugs?”
AI in drug discovery sounds like science fiction until you realize that the entire process — from identifying disease targets to simulating molecular interactions to predicting clinical trial outcomes — can be partially automated with modern AI models. And pharma companies know exactly where the money is.
Why Pharma Is So Interested
The traditional drug discovery process takes 10-15 years and costs $2.6 billion per approved drug. 90% of drug candidates fail in clinical trials. AI is dramatically reducing the time and cost of finding promising drug candidates, which means faster patents and earlier revenue. Every major pharma company needs this.
The Data Moat Is the Real Advantage
AI can analyze molecular structures, predict disease mechanisms, and simulate drug interactions much faster than humans. But the data it trains on — decades of clinical trial results, genetic databases, protein structures — that’s where the competitive advantage will live. Companies that own the data own the AI.
What’s Actually Working
Several AI-designed drugs are already in clinical trials, with promising early results. The most notable cases involve diseases with well-understood protein targets, where AI can efficiently simulate millions of potential drug compounds and narrow down to the most promising candidates.
The companies betting on AI in drug discovery aren’t just chasing a trend. They’re chasing a paradigm shift in how drugs get discovered.
